Press releases – Oncopeptides

Nomination Committee appointed in respect of AGM 2019 in Oncopeptides

October 15, 2018 - Other press release

Stockholm - October 15, 2018 - According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on 17 May 2018, the Nomination Committee...

Oncopeptides to present at the Jefferies London Healthcare Conference on November 14th

October 12, 2018 - Other press release

Stockholm – October 12, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present at Jefferies London Healthcare Conference on November 14th at 3.20 PM local time (GMT), t...

First patient starts treatment with Ygalo® in Oncopeptides’ Phase II study BRIDGE in RRMM patients with renal impairment

September 18, 2018 - Other press release

Stockholm – 18 September 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the first patient has started treatment in the company's Phase II BRIDGE trial designed to study the Pharmacokinetics (PK...

Number of shares and votes in Oncopeptides

August 31, 2018 - Regulatory press release

Stockholm —31 August, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incen...

Anders Martin-Löf has been appointed as the new CFO of Oncopeptides

August 9, 2018 - Regulatory press release

Stockholm – August 9, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Anders Martin-Löf, has been appointed as the new CFO of Oncopeptides and will join the company in No...

Number of shares and votes in Oncopeptides

July 31, 2018 - Regulatory press release

Stockholm —31 July, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incen...

Interim Report April-June 2018

July 13, 2018 - Regulatory press release

“General knowledge and understanding of Oncopeptides and our clinical strategy has greatly increased during the spring”

Oncopeptides present updated interim data from the ongoing HORIZON trial with Ygalo® at the 23rd Congress of The European Hematology Association (EHA)

June 15, 2018 - Regulatory press release

Stockholm – June 15, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they are presenting updated interim data with Ygalo® (melflufen) from the ongoing HORIZON trial at the 23rd EH...

Oncopeptides to present at the Jefferies Healthcare Conference in New York on June 7th

May 29, 2018 - Other press release

Stockholm – May 29, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present at Jefferies annual Healthcare Conference in New York on June 7th at 1.30PM EST, the presentation w...

Bulletin from the Annual General Meeting in Oncopeptides AB (Publ)

May 17, 2018 - Regulatory press release

Stockholm, Sweden – 17 May 2018 – Oncopeptides AB (publ)’s (ONCO) Annual General Meeting 2018 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolu...

Oncopeptides AB Interim report January – March 2018

May 17, 2018 - Regulatory press release

Stockholm — May 17, 2018 — Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the first quarter 2018 report.

Oncopeptides has appointed a Clinical Advisory Board consisting of internationally recognized researchers within clinical development in hematology

April 23, 2018 - Other press release

Stockholm – April 23 2018 – Oncopeptides AB (Nasdaq Stockholm, ONCO) today announced that the company has appointed a Clinical Advisory Board. The aim is to identify development opportunities both wit...

Oncopeptides Annual Report for 2017

April 18, 2018 - Regulatory press release

Stockholm – April 18 2018 – Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Annual Report for 2017 now is available at the company’s website: www.oncopeptides.com.

Preparing for commercialisation of Ygalo®

April 18, 2018 - Other press release

Stockholm - 18 April 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) yesterday announced the notice for the AGM in which the Nomination Committee is proposing two new candidates for the Board of Directors....

ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)

April 17, 2018 - Regulatory press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra T...

First patient starts treatment in Oncopeptides’ Phase I / II ANCHOR study with Ygalo®

April 12, 2018 - Other press release

Stockholm - 12 April 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the first patient has started treatment in the company's Phase I / II ANCHOR trial designed to study Ygalo® in ...

Number of shares and votes in Oncopeptides

March 29, 2018 - Regulatory press release

Stockholm - March 29, 2018 - Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 3,980,000 shares, which...

Oncopeptides strengthens its management team with Dr Christian Jacques as EVP Clinical Strategy and Chief Scientific Officer

March 26, 2018 - Regulatory press release

Stockholm – March 26th, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has broaden its management team with the appointment of Dr Christian Jacques as Executive Vice President C...

Oncopeptides has completed a directed share issue of approximately SEK 314 million

March 22, 2018 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...

Oncopeptides intends to make a directed share issue

March 21, 2018 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...

Additional patent protection for Ygalo® granted in Japan until October 2033

March 8, 2018 - Other press release

Stockholm - March 8, 2018 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the Japanese Patent Office (JPO) recently issued a notice that they will grant an additional Japanese patent to...

Oncopeptides AB Year-end report 2017

February 22, 2018 - Regulatory press release

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the Year-end report 2017. “With increasing clinical data the possible role for Ygalo® in helping patients with myeloma beco...